Raymond James & Associates Axsome Therapeutics, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 8,701 shares of AXSM stock, worth $737,670. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,701

Previous 8,643 0.67%

Holding current value

$737,670

Previous $695,000 12.37%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$78.93 - $95.84 $4,577 - $5,558	58 Added 0.67%	8,701 $781,000
Q2 2024 Jul 19, 2024	SELL	$65.72 - $80.5 $12,223 - $14,973	-186 Reduced 2.11%	8,643 $695,000
Q1 2024 Apr 22, 2024	BUY	$69.39 - $97.64 $236,758 - $333,147	3,412 Added 62.99%	8,829 $704,000
Q4 2023 Jan 16, 2024	SELL	$57.42 - $83.61 $2,928 - $4,264	-51 Reduced 0.93%	5,417 $431,000
Q3 2023 Oct 24, 2023	SELL	$69.25 - $82.21 $180,257 - $213,992	-2,603 Reduced 32.25%	5,468 $382,000
Q2 2023 Jul 25, 2023	BUY	$58.41 - $90.35 $181,071 - $280,085	3,100 Added 62.36%	8,071 $579,000
Q1 2023 Apr 14, 2023	SELL	$58.39 - $75.0 $112,283 - $144,225	-1,923 Reduced 27.89%	4,971 $306,000
Q4 2022 Feb 08, 2023	BUY	$39.94 - $79.72 $38,861 - $77,567	973 Added 16.43%	6,894 $531,000
Q3 2022 Oct 25, 2022	BUY	$36.06 - $69.85 $540 - $1,047	15 Added 0.25%	5,921 $264,000
Q2 2022 Aug 12, 2022	BUY	$21.74 - $46.75 $6,021 - $12,949	277 Added 4.92%	5,906 $226,000
Q1 2022 May 11, 2022	BUY	$23.7 - $41.39 $4,621 - $8,071	195 Added 3.59%	5,629 $233,000
Q4 2021 Feb 08, 2022	BUY	$30.7 - $43.36 $166,823 - $235,618	5,434 New	5,434 $205,000
Q3 2021 Nov 02, 2021	SELL	$19.91 - $68.26 $142,037 - $486,966	-7,134 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$50.63 - $73.5 $166,977 - $242,403	3,298 Added 85.97%	7,134 $481,000
Q4 2020 Feb 12, 2021	SELL	$66.31 - $86.52 $11,073 - $14,448	-167 Reduced 4.17%	3,836 $313,000
Q2 2020 Jul 28, 2020	SELL	$49.87 - $98.69 $13,165 - $26,054	-264 Reduced 6.19%	4,003 $329,000
Q1 2020 Apr 21, 2020	SELL	$41.2 - $101.31 $140,409 - $345,264	-3,408 Reduced 44.4%	4,267 $251,000
Q4 2019 Feb 12, 2020	SELL	$16.71 - $106.24 $262,280 - $1.67 Million	-15,696 Reduced 67.16%	7,675 $793,000
Q3 2019 Nov 07, 2019	SELL	$20.24 - $29.16 $40,480 - $58,320	-2,000 Reduced 7.88%	23,371 $473,000
Q2 2019 Aug 06, 2019	BUY	$13.46 - $25.75 $341,493 - $653,303	25,371 New	25,371 $653,000

Others Institutions Holding AXSM

# of Institutions

325

Shares Held

37.7M

Call Options Held

912K

Put Options Held

855K

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.64B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Axsome Therapeutics, Inc. Transaction History